Stivarga (Regorafenib; Bayer/Amgen) Drug Analysis 2016-2025 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Stivarga" drug pipelines has been added to ResearchAndMarkets.com's offering.

Stivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], and fibroblast growth factor receptor [FGFR]), stromal, and oncogenic (KIT, RET, and B-Raf) kinases.

VEGF-directed agents are a key target in colorectal cancer following the success of Avastin (bevacizumab; Genentech/Roche/Chugai). The anti-angiogenic effect of Stivarga was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging (MRI). In such in vivo models,

Stivarga demonstrated anti-angiogenic activity in animal tumor models, inhibition of tumor growth, and antimetastatic activity. A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after dosing.

Key Topics Covered:

Product Profiles

Stivarga: Colorectal cancer (CRC)

Stivarga: Hepatocellular carcinoma (HCC)

List of Figures

Figure 1: Stivarga for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Stivarga for colorectal cancer

Figure 3: Drug assessment summary of Stivarga for colorectal cancer

Figure 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

Figure 5: Stivarga for HCC - SWOT analysis

Figure 6: Drug assessment summary of Stivarga for HCC

Figure 7: Drug assessment summary of Stivarga for HCC

List of Tables

Table 1: Stivarga drug profile

Table 2: Stivarga pivotal trial data in colorectal cancer

Table 3: Stivarga ongoing trials in colorectal cancer

Table 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 5: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25

Table 6: Stivarga drug profile

Table 7: Stivarga pivotal trial data in HCC

Table 8: Stivarga Phase II data in HCC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/53tzzk/stivarga?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs